Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. (Q50896680)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 November 2012

Language	Label	Description	Also known as
English	Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.	scientific article published on 13 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

pharmacokinetics

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Thomas Dieterle

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Christoph Mamot

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Reto Ritschard

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Gregor Stehle

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lukas Bubendorf

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Christoph Hilker

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Stefanie Deuster

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Richard Herrmann

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Christoph Rochlitz

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

13 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1234-1241

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin in sterically stabilized liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug delivery systems: entering the mainstream

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of ligand-targeted liposomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970476-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70476-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23153506%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50896680&oldid=1543950961"